Indivior Pharmaceuticals, Inc. INDV
Set alert
36.28 USD +0.91 +2.57%
At close · Nov 2
36.30 +0.02 +0.06%
After hours · Nov 2, 4:00 PM ET
35.32 Day range 37.01
27.68 52-week range 42.81
- YTD
- +1.11%
- 1 year
- +23.53%
- Open
- 35.43
- Prev close
- 35.37
- Mkt cap
- 4.28B
- Vol
- 4.87M
- Avg vol
- 2.42M
- EPS
- 3.57
- P/E
- 10.16
- Div yield
- 0.00%
More statistics
- Low
- 35.32
- High
- 37.01
- Forward P/E
- 8.05
- Beta
- 1.13
- Short ratio
- 3.89
- Inst. own
- 104.85%
- Dividend
- 0.00
- Ex-div date
- Nov 2, 2026
- Earnings
- Feb 25, 2027
- 50-d avg
- 35.20
- 200-d avg
- 35.66
- 1y target
- 49.50
1D chart
Signals (71)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | 3:58 PM | 16 hours ago |
| SMA: Bearish | 3:55 PM | 16 hours ago |
| SMA: Bullish | 3:52 PM | 16 hours ago |
| MACD: Buy Signal | 3:52 PM | 16 hours ago |
| MACD: Sell Signal | 3:51 PM | 16 hours ago |
| MACD: Buy Signal | 3:47 PM | 16 hours ago |
| MACD: Sell Signal | 3:41 PM | 16 hours ago |
| MACD: Buy Signal | 3:33 PM | 16 hours ago |
| MACD: Sell Signal | 3:31 PM | 16 hours ago |
| MACD: Buy Signal | 3:30 PM | 16 hours ago |
| RSI: Oversold | 3:25 PM | 16 hours ago |
| RSI: Oversold | 3:18 PM | 17 hours ago |
| SMA: Bearish | 3:12 PM | 17 hours ago |
| SMA: Bullish | 3:06 PM | 17 hours ago |
| SMA: Bearish | 3:04 PM | 17 hours ago |
| MACD: Sell Signal | 2:55 PM | 17 hours ago |
| MACD: Buy Signal | 2:54 PM | 17 hours ago |
| MACD: Sell Signal | 2:28 PM | 17 hours ago |
| RSI: Overbought | 2:16 PM | 18 hours ago |
| SMA: Bullish | 2:02 PM | 18 hours ago |
Newest 20 of 71.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 49.50 +36.4% upside
Now 36.28
- Target (low)
- 45.00
- Target (mean)
- 49.50
- Target (high)
- 53.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 1.22 | 1.22 – 1.22 | 0.82 | +48.8% | 337.90M | -5.6% | 1 |
| Next quarter | 0.9395 | 0.859 – 1.02 | 0.96 | -2.1% | 328.00M | +3.5% | 2 |
| Current year | 4.42 | 4.36 – 4.47 | 2.50 | +76.6% | 1.33B | +7.5% | 2 |
| Next year | 4.51 | 3.89 – 4.89 | 4.42 | +2.1% | 1.40B | +5.1% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Barclays | Maintained | Overweight | Overweight |
| Aug 5, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jun 18, 2026 | Barclays | Initiated | — | Overweight |
| Jan 12, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 31, 2025 | Piper Sandler | Reiterated | Overweight | Overweight |
| Oct 30, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 27, 2025 | Craig-Hallum | Maintained | Buy | Buy |
| Aug 6, 2025 | HC Wainwright & Co. | Initiated | — | Buy |
| Jun 30, 2025 | Craig-Hallum | Maintained | Buy | Buy |
| Mar 6, 2025 | Piper Sandler | Maintained | Overweight | Overweight |
| Oct 25, 2024 | Piper Sandler | Reiterated | Overweight | Overweight |
| Oct 11, 2024 | Craig-Hallum | Maintained | Buy | Buy |
| Oct 11, 2024 | Piper Sandler | Reiterated | Overweight | Overweight |
| Sep 13, 2024 | Piper Sandler | Reiterated | Overweight | Overweight |
| Jul 23, 2024 | Piper Sandler | Initiated | — | Overweight |
| Jul 10, 2024 | Craig-Hallum | Maintained | Buy | Buy |
| Apr 3, 2024 | Craig-Hallum | Initiated | — | Buy |